Aβ	amyloid-beta
AChR	acetylcholine receptor
AD	Alzheimer’s disease
AED	antiepileptic drug
AHP	afterhyperpolarization
AMPA	α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APP	amyloid precursor protein
ASD	autism spectrum disorder
BACE	β-site APP cleaving enzyme
BK	big conductance K+ channels
CA	cornu ammonis
CENTRAL	Cochrane Central Register of Controlled Trials
CCB	calcium channel blocker
CNS	central nervous system
CRS	Cochrane Register of Studies
DAG	diacylglycerol
Dynlt1b	dynein light chain Tctex-type 1
DHP	dihydropyridine
EC	entorhinal cortex
ER	endoplasmic reticulum
Gαq/11	α-subunit of the heterotrimeric Gq/11 protein
GABA	gamma-aminobutyric acid
GBR	GABA B receptor
GPCR	G-protein-coupled receptor
HC	hippocampus
HVA	high voltage-activated
ICTRP	International Clinical Trials Registry Platform
InsP3	inositoltrisphosphate
JIP	c-Jun N-terminal kinase-interacting protein
LTCC	low-threshold Ca2+ current
LTCS	low-threshold Ca2+ spike
LTP	long-term potentiation
LVA	low voltage-activated
mAChR	muscarinic acetylcholine receptor
MCI	mild cognitive impairment
M1/M3	muscarinic receptor type 1/3
MS	medial septum
MS-DBB	medial septum-diagonal band of Broca
NgR	Nogo receptor family
NMDA	N-methyl-D-aspartate
NPY	neuropeptide Y
OLM	outer lacunosum-moleculare layer
PCG	posterior cingulate gyrus
PD	Parkinson’s disease
PKC	protein kinase C
PLC	phospholipase C
PV	parvalbumin
qPCR	quantitative polymerase chain reaction
RCT	randomized controlled trial
RyR	ryanodine receptor
REM	rapid eye movement
ROS	reactive oxygen species
R-type	“resistant”-type Ca2+ channel
sAPP	secreted APP
SST	somatostatin
SFG	superior frontal gyrus
T-type	“transient”-type Ca2+ channel
VGCC	voltage-gated Ca2+ channel